Effects of beraprost sodium sustained-release tablet on improvement of insulin resistance in patients with type 2 diabetes with obesity in a Double-Blinded, Randomized, Placebo-Controlled, Crossover Trial.
Not Applicable
Recruiting
- Conditions
- Patients with type 2 diabetes and obesity
- Registration Number
- JPRN-UMIN000008469
- Lead Sponsor
- Graduate School of Medicine, University of Tokyo Department of Metabolic Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with bleeding tendency Patients with Type 1 diabetes or secondary diabetes Patients with severe renal dysfunction Patients with liver dysfunction Patients with a past history if drug hypersensitivity Pregnant women or women with breast-feeding Patients who took prostaglandin derivatives within 3 months Patients whose prescription drugs were changed within 3 months All Patients who is unsuitable for this trial at a physician's discretion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effects of beraprost sodium sustained-release tablets and placebo on the insulin resistance by glucose infusion rate on euglycemic hyperinsulinemic clamp
- Secondary Outcome Measures
Name Time Method 1. HOMA-IR (Homeostasis model assessment-Insulin Resistance) To evaluate the effects on the insulin resistance. 2. Fasting blood glucose, Glycoalbumin, HbA1c To evaluate the effects on the glycemic control. 3.ADMA, %FMD To evaluate the effects on the vascular endotherial function.